Corporate News

Peppermint VC realizes lucrative exit…


Peppermint VC realizes lucrative exit through the acquisition of next-generation chemotherapy agent CAP7.1 from German biotech CellAct by Mundipharma

CellAct Pharma GmbH together with the Mundipharma global network has announced a new deal for the development and commercialization of smart chemotherapy (CAP7.1) with a total deal value exceeding 250 million €. Read more

CEVEC licenses CAP(R) technologies for the development and commercialization of vaccines against Zika Virus infections

Agreement marks an important step in establishing CAP(R) technologies as the new global industrial standard for viral vector and vaccine development

Cologne. CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed an exclusive license agreement with NewLink Genetics (NASDAQ:NLNK) for use of its proprietary CAP(R)GT and CAP(R)Go cell lines in the development and commercialization of products for the treatment and prophylaxis of Zika virus infections. Read more

Peppermint VenturePartners closes Series-C financing round of Miracor Medical Systems GmbH

Miracor’s Chairman of the Board: “We are proud to have PVP joining our Investors”

Berlin. Peppermint VenturePartners led the recent Series-C financing of Miracor Medical Systems GmbH with an investment from its Peppermint CBF-1 fund. The total amount raised in the Series-C is currently € 7 Million. Miracor seeks to complete Series-C with another € 8 Million. Read more

Helmholtz validation funding extended, facilitating further projects

Developing pioneering technologies and making them attractive for industry often requires a great deal of patience and perseverance. The Helmholtz Validation Fund (HVF) is therefore providing support to a number of particularly promising projects carried out by research teams in the Helmholtz

Association. A total of 21 projects were selected for the first funding period from 2011 to 2015. Following a successful evaluation process, the programme will now continue from 2016 to 2020. The first three projects to be funded in the new programme phase were selected this December by the experts on the decisionmaking board. These projects could pave the way to discovering new and better ways of diagnosing and treating diseases such as cancer, osteoporosis and Alzheimer’s. Read more

PVP expands its portfolio by labfolder – the digital laboratory notebook software for research


The Charité Biomedical Fund (CBF-1), managed by Peppermint VenturePartners (PVP), is the lead investor of the current financing round of labfolder – the digital laboratory notebook software for research. labfolder closes a seven-digit growth financing round for further development of the software platform, and expanding marketing and international sales. Read more